The way I read your post is there are two groups; both with virtually the same cure rates.
I think the major players have been telling us for some time that they are going for pan-genotypic. It's almost a moot point which is better.
By the way; it is possible to be infected with more than one genotype, and sometimes genotyping tests are not 100% conclusive.
Perhaps I am wrong, but I am not seeing a lot of difference between real world cure rates and trial cure rates; well, in GILD and Abbvie IFN free treatments; its a few % points
(in trials a lost patient may count as a failure. Some stopped dosings due to AE's still result in cures)
News 
Market Data 
Discover 
